DOES ANTI-REFLUX SURGERY SYMPTOMATICALLY IMPROVE EXTRA-OESOPHAGEAL SYMPTOMS AND QUALITY OF LIFE IN GASTRO-OESOPHAGEAL REFLUX DISEASE

C A Lynch, S Efojo, R Sathyamurthy, A Mansur; Birmingham Heartlands Hospital, Birmingham, United Kingdom

10.1136/thoraxjnl-2013-204457.40

Introduction Extra-oesophageal (ie laryngeal, pharyngeal and pulmonary) symptoms of gastro-oesophageal reflux (GOR) are common clinical problems. GOR can cause a chronic cough and its prevalence is higher in asthmatics than in the general population. Proton pump inhibitors (PPI) are the most effective available therapy but in those who remain symptomatic despite optimal medical therapy anti-reflux surgery is considered.

Method At our central England teaching hospital a database was set up for all respiratory patients with GOR who were referred for anti-reflux surgery. Symptoms were assessed at baseline (pre-surgery), 3 months post surgery and 12 months post surgery using the asthma quality of life questionnaire (AQLQ; range; 0 = no cough -10 worst cough).

Results A total of 61 patients (70% females) with mean age of 48.64 (range 20 - 78 years) were analysed. 34 patients were asthmatics and 26 patients had a chronic cough. 1 patient was excluded as they had vocal cord dysfunction.

All patients had significant GOR confirmed by oesophageal manometry and pH reflux studies (mean DeMeester score of 46.6 (SD = 38.4, normal range <14.72), hypotonic mean lower oesophageal sphincter pressure of 5.7 mmHg (SD 3.78, normal range = 12–25) and a mean% reflux time of 11.9 (SD 8.98, normal range <4%)). The baseline mean FEV1 in the asthma group was 2.08 (mean FEV1/FVC 0.72) compared to 2.61 (mean FEV1/FVC 0.81) in the cough group.

There was significant improvement in reflux symptoms. In the asthma group, the mean AQLQ score improved from baseline (3.05, SD = 0.8) to 3 months post surgery (3.68, SD = 0.9) (p = 0.0235), and 12 months post surgery (3.5, SD = 1.2) which did not reach statistical significance (p = 0.1) [see Figure 1]. There was also marked improvement in the cough symptom score from baseline (7.0, SD = 2.3) to 3 months post surgery (2.8, SD = 3.1) [p = <0.0001] [see Figure 1].

Conclusion In patients with evidence of severe GOR who remain symptomatic despite optimal medical management, anti-reflux surgery can improve cough and asthma related quality of life.

Abstract S33 Figure1 Does anti-reflux surgery symptomatically improve extra-oesophageal symptoms and quality of life in gastro-oesophageal reflux disease
We have used in this study a combination of genome expression profiling and cytokine arrays to screen for candidates mediating MSC homing to two different cancer cell lines: A549 and MDMB231. We found a variety of interleukines and cytokines already described as players in the process, such as IL6, IL8, CCL2. Additionally, from in vitro migration and invasion assays, we show that CXCR4 is a major player in this mechanism being the essential MSC receptor for the process to occur. Furthermore, we have identified MIF as the major trigger for MSC homing, being secreted from tumour cells at high levels.

For the first time, we have identified in this study a novel axis: MIF-CXCR4, showing a physical interaction between them and validating their essential role in vitro and in vivo. Importantly, knocking down the expression of CXCR4 in MSCs or MIF in tumour cells, drastically decreased MSC recruitment to tumours in a in vivo model of lung metastasis.

A better understanding of MSC homing players towards tumours will help the development of novel strategies in their use as vehicles in cancer cell therapy.

**S36** DIFFERENTIATION OF TUBERCULOSIS AND SARCOIDOSIS BY TRANSCRIPTIONAL PROFILING OF IMMUNE RESPONSES IN MEDIASTINAL LYMPH NODE SAMPLES

1GS Tomlinson, 1G Hardavella, 1J Brown, 1S Suczyn, 1N Navani, 1N Thomas, 1BM Chain, 1SM Janes, 1M Noursadeghi; 1University College London, London, United Kingdom; 2University College London Hospital, London, United Kingdom

Introduction and Objectives Differentiating tuberculosis and sarcoidosis can be difficult, particularly in the context of mediastinal lymphadenopathy, because both diseases are characterised by overlapping clinical phenotypes and histologically similar granulomatous inflammation. Currently, diagnosis relies heavily on microbiological confirmation of tuberculosis which is only available in <50% of cases. Therefore, novel diagnostic strategies are needed to prevent morbidity associated with delayed or inappropriate treatment. We tested the hypothesis that genome wide transcriptional profiling of mediastinal lymph node samples obtained by minimally invasive endobronchial ultrasound guidance could identify gene signatures that differentiate tuberculosis and sarcoidosis.

Methods In vivo immune responses were compared in mediastinal lymph node biopsies obtained via endobronchial ultrasound guidance from patients with tuberculosis, sarcoidosis or non-granulomatous disease using genome-wide transcriptional profiling. Machine learning algorithms were used to test the discriminatory power of identified gene signatures which distinguished granulomatous from non-granulomatous disease or tuberculosis from sarcoidosis.

Results Comparison of lymph node genomewide transcriptional profiles by principal component analysis revealed clear differences between granulomatous and non-granulomatous disease. Granulomatous profiles showed significant enrichment for genes involved in antigen presentation, inflammatory responses, innate immune responses and T cell activation, in keeping with the processes involved in granuloma generation. As expected, sarcoidosis and tuberculosis sample profiles were very similar, however, significant gene expression differences were still evident between these two groups. In particular, several genes related to development of granuloma architecture were more highly expressed in sarcoidosis samples. Next we used machine learning tools in order to test the discriminatory power of differentially expressed gene signatures and found that the support vector machines algorithm correctly classified up to 97% of granulomatous and non-granulomatous disease cases. Importantly, this technique successfully distinguished sarcoidosis from tuberculosis in up to 100% cases.

Conclusions Transcriptomic analysis of lymph node samples from the site of disease identifies gene signatures that can reliably distinguish tuberculosis from sarcoidosis using computational classification tools. Our data highlight the superior discriminatory power of multiple gene expression differences over a single marker in complex disease and generate a pathway for biomarker discovery in the management of tuberculosis and sarcoidosis.

**S37** MATRIX METALLOPROTEINASES DRIVE COLLAGEN DEGRADATION AND LEUKOCYTE MIGRATION IN HUMAN TUBERCULOSIS: CLINICAL AND CELLULAR STUDIES

1S Sathyamoorthy, 1JS Friedland, 2L Teza, 3PF Elkingston; 1Imperial College, London, United Kingdom; 2University of Southampton, Southampton, United Kingdom

Introduction and Objectives Tuberculosis (TB) causes disease worldwide and multi-drug resistance is rising. Matrix metalloproteinases (MMPs) cause immunopathological lung matrix destruction, which results in transmission, morbidity and mortality. We specifically investigated collagenases in TB, studying secreted MMP-1 and MMP-8, and membrane bound MMP-14.

Methods Plasma was prospectively collected from TB patients (n = 151), respiratory symptomatics (n = 109) and controls (n = 120). Plasma MMP concentrations were measured by Luminex bead array. Induced sputum MMP-14 mRNA from TB patients and controls was quantified by RT-PCR. MMP-14 expression in TB patient biopsies was studied by immunohistochemistry. Human monocytes were stimulated with Mycobacterium tuberculosis (MtB) H37Rv or Conditioned Media from MtB infected monocytes (CoMtB) and MMP-14 measured using flow cytometry. Fluorescent microscopy detected MMP-14 and monocyte driven fluorescent collagen degradation. Monocyte migration was measured by the agarose spot assay.

Results Plasma MMP-1 was elevated in TB (median 229pg/ml) compared to controls (median 2pg/ml; p<0.001). MMP-8 was increased in TB (median 835pg/ml) compared to both respiratory symptomatics (median 3547pg/ml; p<0.001) and controls (median 3236pg/ml; p<0.001), and discriminated TB from respiratory symptomatics with moderate predictive ability, with an area under the curve of 0.79 by receiver operating characteristic analysis. In induced sputum, MMP-14 mRNA (normalised to β-actin) was increased 3.3-fold in TB compared to controls (p<0.05) and mRNA levels positively correlated with the extent of lung infiltration on chest radiograph (r = 0.483; p<0.05). Macrophages of TB granulomas in patient biopsies stained strongly positive for MMP-14. MtB increased monocyte MMP-14 surface expression 31.7-fold (p<0.05) and CoMtB 17.5-fold (p<0.01), secondary to increased mRNA. MtB-infected monocytes degraded collagen, with co-localised MMP-14 surface expression. Monocytes migrated to the edge of CoMtB-impregnated agarose drops, expressing MMP-14 on migration. Inhibition of MMP-14 activity with a neutralising antibody, decreased MtB driven collagen degradation by 73% (p<0.001) and CoMtB driven monocyte migration by 44% (p<0.001). Inhibition of chemokine signalling using pertussis toxin reduced CoMtB driven MMP-14 surface expression by 35% (p<0.05).

Discussion Collagen destruction is critical to pathogenesis in pulmonary TB, and these data implicate three collagenases, MMP-1, -8 and -14, in causing immunopathology and regulating leukocyte migration. MMPs may represent novel diagnostic and therapeutic targets.
Corrections


The correct author list should read as:

S Lourenco, V H Teixeira, T Kalber, A Floto, S M Janes; Lungs for Living Research Centre, London, UK.

*Thorax* 2014;69:239. doi:10.1136/thoraxjnl-2013-204457.42.corr1